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Summary 
The analysis of chromosomal deletions overlapping at the albino locus in the 
mouse has led to the postulation of a number of loci in this region essential for 
viability. One of these, the perinatal survival locus, is thought to be important for the 
differentiation of the liver since its deletion results in the deficiency of a set of liver-
specific enzymes and ultrastructural abnormalities in the hepatocyte. By differential 
cDNA Screening we have isolated and examined the expression of a panel of mRNAs 
influenced by deletion of the locus. This has been done in an attempt to elucidate the 
role of the normal gene product. In addition, as a prelude to cloning the perinatal 
survival locus, a long-range restriction map has been established onto which the extents 
of albino locus deletions are being placed. 
Introduction 
The classical genetic approach to understanding development and differentiation 
is the generation of mutations which arrest or alter these processes. The isolation and 
characterization of the affected genes may follow, according to the mutagen employed. 
The albino locus, designated c, on chromosome 7 in the mouse, was an early target 
owing to the ease of identifying mutational events through changes in coat colour. From 
the pleiotropic effects of a set of radiation induced £ alleles it was inferred that the 
mutations represented deletions of various sizes overlapping at c (Gluecksohn-Waeisch 
et al., 1974; Gluecksohn-Waeisch, 1979). Subsequently, thirty-seven deletions have been 
assigned to twelve groups on the basis of detailed complementation analysis of the 
phenotypes they engender (Russell et al., 1979; 1982). Amongst the phenotypes are 
recessive lethalities (Russell and Raymer, 1979) and at least three regions linked to c 
essential for early embryonic development and one for survival beyond birth have been 
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proposed from the complementation map (Russell et al., 1982; Niswander et al., 1988). 
The perinatal lethality has been investigated extensively by Gluecksohn-Waeisch and her 
colleagues, and the observations of the phenotype would seem to suggest that the 
perinatal survival locus is required for the füll biochemical differentiation of the 
hepatocyte (Gluecksohn-Waelsch, 1979; 1987). 
The perinatal lethal phenotype is associated most strikingly with a reduction in 
activities of a number of enzymes in the liver and with ultrastructural abnormalities of 
hepatocytes and cells of the proximal convoluted tubules of the kidney (Trigg and 
Gluecksohn-Waelsch, 1973). The deficient enzymes include glucose-6-phosphatase 
(GöPase), tyrosine aminotransferase (TAT), serine dehydratase (SDH) and phosphoenol-
pyruvate carboxykinase (PEPCK) (Erickson et al., 1968; Thorndike et al., 1973; 
Gluecksohn-Waelsch et a l , 1974; Loose et al., 1986). A large number of other enzymes 
remain uninfluenced by the mutation, attesting to its specific nature (Thorndike et al., 
1973; Gluecksohn-Waelsch, 1979). This accords with the results of two-dimensional gel 
electrophoresis of liver extracts which have shown that very few Polypeptides are 
visibly altered in abundance (Baier et al., 1984). In the case of PEPCK and TAT it has 
been established that the decreased enzyme activities result from lower levels of steady-
state mRNA (Schmid et al., 1985; Loose et a l , 1986) and impaired transcription has 
been imputed from nuclear run-on assays partly to be responsible for this (Loose et al., 
1986; E. Schmid, S.R. et al., unpublished observations). Aldolase B and metallothionein 
I have recently been added to the list of mRNAs reduced in abundance (Sala-Trepat et 
al., 1985; DeFranco et al., 1988). The synthesis of serum proteins by the liver is also 
diminished (Garland et al., 1976). However, this has no basis in decreased trans-
criptional rates (Sala-Trepat et al., 1985) and may be a consequence of the ac-
companying ultrastructural lesions (see below). The absence of a gene dosage effect on 
enzyme activities in heterozygotes was taken as an early indication that the perinatal 
survival locus acted in trans (Russell et al., 1969). Subsequently, cell fusion experiments 
(Cori et al., 1981; 1983), the mapping of the genes encoding the affected enzymes to 
chromosomes other than 7 (Lern and Fournier, 1985; Müller et al., 1985; Peterson et al., 
1985), or the direct demonstration that their structural loci were not deleted in the 
mutant mice (Schmid et al., 1985; Loose et al., 1986) came as further evidence that the 
locus acted in trans and might be regulatory in nature. 
Most of the enzymes influenced by the mutation play a role in gluconeogenesis 
and the deficiency of GöPase contributes to the intractable hypoglycaemia regarded as 
the cause of death of the newbora homozygotes (Erickson et al., 1968). These enzymes 
are controlled by dietary Status and their expression is regulated by glucagon, via 
cAMP, or glucocorticoids, or both (Greengard, 1970; Granner and Beale, 1985). In 
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addition, although their onsets of expression may differ, enzyme activities rise in the 
immediate post-natal period (Greengard, 1970), presumably in response to the hormonal 
changes occurring at that time. The precocious induction observed in fetuses after in 
utero administration of glucagon or cAMP underlines the importance of hormones in the 
developmental activation (Greengard, 1970; Garcia Ruiz et al., 1978). It was an early 
Observation that in the albino lethal mice GöPase activity was not inducible in late 
gestation fetuses (Erickson et al., 19Ö8). TAT and PEPCK mRNA levels, likewise, fall 
to respond to their activators in livers of the mutant mice (Schmid et al., 1985; Loose et 
al., 198ö) but, whilst the characteristic post-natal increase is abolished, pre-natal mRNA 
levels are identical to wild-type mice (Donner et al., 1988). Taken together, these 
observations have given rise to the hypothesis that the locus encodes a factor that 
confers on the set of genes the competence to respond to hormonal activation (Glueck-
sohn-Waelsch, 1987). 
A second feature of the perinatal lethal phenotype is the disruption of the 
integrity of some intracellular membranes, specifically of the hepatocyte and cells of the 
proximal convoluted tubule of the kidney, as observed by electron microscopy. The 
membranes of the nucleus, rough endoplasmic reticulum and Golgi apparatus are 
involved. There is a tendency to dilation and vesiculation of these membrane structures 
and loss of membrane-bound ribosomes. The abnormalities are first detectable at day 18 
of gestation, and are displayed by an increasing number of cells until birth (Trigg and 
Gluecksohn-Waelsch, 1973). Analysis of microsomal Polypeptide populations failed to 
reveal a significant difference between wild-type and mutant material, however 
(Erickson et al., 1974). The relationship the two characteristics of the phenotype, the 
biochemical and ultrastructural abnormalities, have to one another is not yet clear, 
especially in view of the fact that the deficient liver enzymes are localized in different 
sub-cellular compartments (Gluecksohn-Waelsch, 1979). 
In order to understand the perinatal lethal phenotype more fully and to elucidate 
the nature and function of the product of the perinatal survival locus two experiments 
are underway. Firstly, we have attempted to identify a broader set of genes influenced 
by the mutation than was previously possible: by differential Screening we have tried to 
collect cDNAs for affected mRNAs whose selection is not limited by the availability of 
enzyme assays. This has been done to identify more rigorously a common denominator 
for the affected genes. Secondly, since the ultimate demonstration of the function of the 
gene depends upon its isolation, we are attempting to clone it from the knowledge of its 
chromosomal location. In keeping with the theme of this book, this communication is a 
review of our progress in both these areas. 
50 
Methods 
Differential Screening of a newborn mouse liver cDNA library. A füll treatment of 
the construction and differential Screening of the newborn mouse liver cDNA library is 
to appear elsewhere (Ruppert et al., 1989). The inserts of the recombinant phage 
isolated were subcloned into Bluescript M13+ (Stratagene) for the purpose of generating 
hybridization probes and partial sequence analysis. Sequencing was performed by the 
chain-termination method using T3 or T7 promoter-specific oligonucleotides to prime 
Klenow Polymerase (Lim and P&ne, 1988). The sequences were compared to those in 
the GEN-Bank data bank. 
Northern analysis. RNA was prepared from various tissues of newborn albino lethal 
(genotype c14CoS/c14CoS) and wild-type littermates (cch/c14CoS and cch/cch) according to the 
method of Krieg et al. (1983). 2S FAZA (Brown and Weiss, 1975) cells were main-
tained in DMEM/HAM F12 (1:1) medium containing 10% fetal calf serum. Two days 
before harvesting for RNA, cells were washed with PBS and induced in complete 
medium in the presence of 3X10"6 M dexamethasone in ethanol or ethanol alone as 
control. Five microgram total RNA was fractionated per lane on 1% agarose/formal-
dehyde gels (Lehrach et al., 1977) followed by transfer in lOx SSC onto Gene Screen 
membranes (NEN), baking and UV-crosslinking. Filters were hybridized at 65-70°C in 
50% formamide; 5x SSC; 50 mM sodium phosphate pH 6.5; 8x Denhardt's Solution; 1% 
SDS and 500 ixgml'1 yeast RNA containing 32P labelled antisense RNA probes. Post-
hybridization washes were O.lx SSC; 1% SDS at 65-80°C. Probes were synthesized 
from appropriate templates by SP6, T3 or T7 polymerases (Melton et al , 1984). 
Additional probes used were the mouse TAT cDNA (S.R., unpublished); the rat SDH 
cDNA (Nöda et al., 1985); a mouse transferrin cDNA (S.R., unpublished, identified by 
homology to the human sequence of Yang et al., 1984) and rat glyceraldehyde-3-
phosphate dehydrogenase (Fort et al., 1985). 
Pulsed-field gel electrophoresis. Very high molecular weight DNA suitable for pulsed-
field gel electrophoresis was prepared from newborn and adult liver by embedding cells 
in low-melting point agarose. The procedure was that of Herrmann et al. (1987), with 
the exceptions that fresh tissues were used and that each 80 LLI block contained the 
equivalent of 0.5xl06 cells. For restriction enzyme digestions, blocks were rinsed 
extensively in TE and placed in 120 |il reaction mix containing the appropriate digestion 
buffer and incubated with up to 20U enzyme (New England Biolabs) for a minimum of 
6 h. In the case of double digestions, blocks were rinsed briefly in water before the 
second incubation. Blocks were loaded directly into the wells of agarose gels without 
further treatment. Pulsed-field gel electrophoresis was carried out in an LKB Pulsaphor 
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apparatus equipped with OFAGE or hexagonal electrode arrays. Gels were 1% agarose, 
except for when resolution of fragments greater than 3000 kb was desired when the 
percentage was reduced to 0.6%. Electrophoresis was conducted in 0.25x TBE (TBE = 
89 mM Tris base; 89 mM boric acid; 2 mM EDTA), with running conditions based on 
those of Vollrath and Davis (1987) and Birren et al. (1988). Size markers were 
multimers of y, and chromosomes of Saccharomyces cerevisiae strain AB972 and 
Schizosaccharomvces pombe. DNA was transferred to Gene Screen (NEN) filters in 
alkali (Jantzen et al., 1987) and immobilized by baking and UV-crosslinking. Hybri-
dizations and washings were performed according to Church and Gilbert (1984). Probes 
were labelled either with [32-P]dCTP by random priming (Feinberg and Vogelstein, 
1984) or with [32-P]UTP by transcription of appropriate templates by SP6, T3 or T7 
RNA polymerases (Melton et al., 1984). Probes used were the tyrosinase cDNA or 
subfragments thereof (Ruppert et al., 1988); a 2.2 kb EcoRLXhoI genomic fragment 
encompassing exon I of the tyrosinase gene (Ruppert et al., 1988); and 12A (Disteche 
and Adler, 1984). 
Animals. Mouse strains carrying the albino lethal deletions c3H and c14CoS were obtained 
from S. Gluecksohn-Waelsch (Albert Einstein College of Medicine, Bronx, New York), 
and c15R60L was provided by L.B. Russell and E.M. Rinchik (Oakridge National 
Laboratory, Tennessee). Each was maintained as a separate line as heterozygotes with 
c* 
Results 
Isolation and characterization of cDNAs representing mRNAs affected by deletion of the perinatal survival locus. 
A cDNA library was prepared from poly(A+) RNA from normal newborn mouse 
liver and duplicate filters were screened with probes representing the newborn liver 
mRNA population of normal or albino lethal mutant (genotype c3H/c3H) mice. Fifty 
plaques out of a plating of 5xl05 showed a more intense hybridization to wild-type than 
mutant probes. Twenty-one of these Signals remained differential through subsequent 
rounds of plaque purification and could be grouped into nine families, XI to X9, on the 
basis of cross-hybridization of their inserts. None proved to represent DNA from the 
albino deletion complex, indicating that a cDNA for the perinatal survival locus had not 
itself been recovered (Ruppert et al., 1989). 
Partial sequence analysis indicated that cDNA X3 represented the mouse PEPCK 
message, by homology to that of the rat (Beale et al., 1985); X4 showed substantial 
homology to human and rat a-fibrinogen cDNAs (80 and 90% identity, respectively; 
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Rixon et al., 1983; Crabtree et al., 1985); X6 to rat serine protease inhibitors (Le Cam 
et al., 1987; Yoon et al., 1987); and the X8 sequence had 90% identity with the rat 
aldolase B cDNA (Tsutsumi et al., 1984). The expression of both the aldolase B and 
PEPCK genes have previously been shown to be influenced by the albino perinatal 
lethal deletions (Sala-Trepat et al., 1985; Loose et al., 1986). The identification of these 
cDNAs in our set indicates the success of the differential Screening approach. The 
isolation of the cDNAs encoding oc-fibrinogen and a serine protease inhibitor amongst 
our set demonstrates that the lesion at the level of the mRNA is not restricted to 
metabolic enzymes. 
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FIG. 1. Postnatal regulation and 
hormone induction of mRNAs 
influenced by the perinatal 
lethality. Total RNA (5 |ig) 
isolated from livers of albino 
lethal mice and newborn 
littermates at the indicated time 
points after birth was analyzed 
by Northern blot hybridization. 
Filters were hyridized with 
antisense RNA probes derived 
from the cDNAs isolated by 
differential Screening, XI to X9, 
and with TAT and SDH cDNAs. 
In the right-hand panel the same 
cDNAs were used to investigate 
the expression of the homo-
logous rat mRNAs in the rat 
hepatoma cell line 2S FAZA 
(Faza) in the presence (+) or 
absence (-) of the synthetic 
glucocorticoid dexamethasone 
(Dex). n.d. indicates no 
expression detected. RNA 
quality and loading was 
controlled by rehybridizing all 
filters to transferrin or glycer-
aldehyde-3-phosphate dehydro-
genase probes. One result with 
transferrin is shown here. 
Northern blot analysis has been used to investigate the expression of the set of 
mRNAs in liver and other tissues, to establish their onset of expression and to deter-
mine in which tissues the mutation has an effect. In addition to the cDNAs XI to X9, 
probes for the mouse TAT (S.R., unpublished) and rat SDH (Nöda et al., 1985) have 
been used. From Fig. 1 it is evident that the level of each of the mRNAs is sub-
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stantially reduced in livers of the mutant mice in comparison to that seen in their 
normal newborn littermates. Some of the mRNAs, such as XI, X2 and X3 (= PEPCK), 
behave like TAT and SDH and show an increase in abundance during the first hours 
after birth, followed by a decline. 
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FIG. 2. Tissue-specific mani-
festation of the phenotype at the 
level of mRNA. RNA (total, 5 
|xg) from various tissues from 
albino lethal mice (A) and their 
wild-type (W) littermates was 
analyzed by Northern blotting. 
The autoradiographs were 
exposed for different times. 
RNA quality and loading was 
controlled as in Fig. 1. The 
apparent reduction in the lane 
marked 'Heart A* is due to 
underloading. 
The mRNAs have the property in common that the highest steady-state levels are 
attained in liver in comparison with other organs (Fig. 2). The spectrum of expression, 
however, differs from the apparently liver-specific, as in the case of SDH, X4, X6, X7 
and X9, to ubiquitous amongst the organs tested, e.g., X5. The influence of the mutation 
clearly extends only to liver and kidney, however. Intriguingly, those mRNAs that are 
expressed in the kidney exhibit different behaviours. Whereas X3/PEPCK and XI 
mRNAs are decreased in kidney of the mutant, others, aldolase B and X5, escape the 
influence. Detection of the mRNAs by in situ hybridization to tissue sections has 
indicated that this difference cannot solely be attributed to expression of the genes in 
different cell populations in the kidney (Ruppert et al., 1989). However, it might be 
relevant that in the rat PEPCK expression is activated by glucocorticoids in the kidney 
(Meisner et al., 1985), whereas aldolase B is not (Munnich et al., 1985). This finding 
has a parallel in the expression of metallothionein I whose mRNA is reduced in liver 
but not in kidney of albino lethal mice, and glucocorticoid responsiveness is apparent in 
the liver but not the kidney (DeFranco et al., 1988). 
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The enzymes traditionally known to be deficient in the albino lethal mice are 
normally subject to regulation by glucagon or glucocorticoids. To begin to examine 
whether the additional mRNAs we have isolated have in common induction by hor-
mones, the expression of their rat homologues was analysed in the rat hepatoma cell 
line 2S FAZA. For those species for which expression could be detected, the abundance 
of the mRNA was clearly elevated after a 46-h treatment with the synthetic glucocor-
ticoid, dexamethasone (Fig. 1). 
Long ränge restriction mapping around the perinatal survival locus. 
We are attempting to isolate the perinatal survival locus from the knowledge of 
its chromosomal location. This has been made possible with the isolation of probes 
mapping to the c locus. Recently, we and others have cloned the cDNAs encoding 
human and mouse tyrosinase (Kwon et al., 1987; Yamamoto et al., 1987; Ruppert et al., 
1988), which is the enzyme encoded at the c locus (Müller et al., 1988) and essential 
for melanin production, and hence crucial for coat colour. This has, in turn, led to the 
cloning of the entire structural gene, which has proven to occupy 70 kb (Ruppert et al., 
1988). Probes from the tyrosinase gene have been used to construct a long-range 
restriction map around c by employing restriction enzymes that cut very rarely in the 
mammalian genome (Brown and Bird, 1986) in combination with pulsed-field gel 
electrophoresis by which very large fragments of DNA can be resolved (reviewed by 
Barlow and Lehrach, 1987). The aim is to superimpose the genetic map of the albino 
deletions onto the molecular map in such a way as to define the minimal region in 
which the perinatal survival locus is located. The following Information is being 
procured: the mapping of the position and extent of the deletions that do and do not 
remove the perinatal survival locus; the orientation of the derived map on the 
chromosome and within it the orientation of the tyrosinase gene so as to indicate the 
direction for chromosomal jumping and Walking. 
The various levels of the mapping exercise are illustrated in Fig. 3. Fig. 3A 
provides a map of some of the relevant complementation groups (modified from Russell 
et al., 1982). Group A, for example, involves the perinatal survival locus and tyrosinase 
but no other known markers. The positions of two deletions belonging to this group, 
deletions c14CoS and c15R60L, have been derived from the use of a probe, 12A, that was 
previously isolated from a library of sorted chromosomes (Disteche and Adler, 1984). 
12A proved to map within the albino deletion complex, but the sequence it recognizes 
is not removed by these two deletions. In addition, the probe must map distal to c, from 
genetic considerations. A crude map, covering approximately 5000 kb, of some very 
large restriction fragments detected by the tyrosinase and 12A probes has been pro-
duced. The limits of the two deletions can be roughly placed within this (Fig. 3B). 
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Legend to FIG. 3. Summary of the long ränge restriction mapping around the perinatal survival locus. A. Complementation map of a set of the deletions at the c locus (modified from Russell et al., 1982). For simplicity, only three of the twelve com-plementation groups are illustrated. Of the deletions referred to in this work, c14CoS and 
C I 5 R 6 O L belong to group A and c3H to E. The boxes indicate six of the loci predicted in this region. tp is the marker taupe and Mod-2 the structural locus for the mitochondrial malic enzyme. B. Restriction map of « 5000 kb surrounding the tyrosinase gene (TYR) and the approximate location of two A group deletions. The deletions are represented by open regions within the filled bars. 12A is an anonymous DNA sequence mapping distal to £ (Disteche and Adler, 1984). C. Restriction sites within 1500 kb of the tyrosinase gene, interpreted from the data in Table 1. The positions of the distal breakpoints of the illustrated deletions were inferred from Information gained with additional enzymes. D. The orientation of the tyrosinase gene within the mapped region derives from the presence of an Xhol site in the first exon and an Narl site in the cloned region 3' to the gene. 
This would indicate deletions of about 1500 kb, which is in accord with genetic and 
cytogenetic considerations which put the c14CoS deletion at lcM, or 2000 kb. 
Table.l 
Fragments Rccognized By 
ENZYME TYR 12A 
Sac II 8 5 0 k b 5 8 0 k b 
Sac II + Bss III! 3 8 0 k b 5 8 0 k b 
Bss HU 1 2 0 0 k b 1 2 0 0 k b 
Sac II +Nae I 3 8 0 k b 5 8 0 k b 
Nae I 9 5 0 k b 9 5 0 k b 
Sac II + Nar I 180 , 3 8 0 , 5 2 0 k b 5 8 0 k b 
Nar I > 1 2 0 0 k b > 1 2 0 0 k b 
Nar I + Xho I 9 0 k b n.t. 
Xhol 1 7 0 k b n.t. 
Restriction fragments detected by the tyrosine (TYR) and 12A probes by pulsed-field 
gel electrophoresis analysis contributed to the maps shown in Fig. 3C and 3D. n.t. not 
tested. 
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A higher resolution mapping has been achieved of the 1500 kb surrounding the 
tyrosinase gene and extending towards the perinatal survival locus. The sizes of 
restriction fragments hybridizing to tyrosinase probes is given in Table 1, and the 
derived map is shown in Fig. 3C. The orientation of the map on the chromosome was 
deduced by linking up the mapping Information for the 12A probe (Table 1). Both 
probes detected BssHII and Nael fragments of similar sizes, but distinct SacII frag-
ments. To demonstrate that the BssHII fragments were indeed the same and that the 
SacII fragments were adjacent, products of complete BssHII followed by partial SacII 
digests were compared. Fig. 4 illustrates the cleavage of the common 1200 kb BssHII 
fragment, via a common 1000 kb intermediate, to the ultimate BssHII:SacII and SacII 
fragments recognized by the tyrosinase and 12A probes have been defined from digests 
with additional, more frequently cutting enzymes (data not shown). 
TYR 
# r-1200 
+ + + 1 + + + + | + Bss HU + - + -
Increasing ^ Increasing ^ Sac // + + + 
380kb h 
1000kb h 
I200kb h 
S a c / / 
I 
Bss HU Sac II 
I I 
r™ri 
Sac II Bss Hll 
I I 
FIG. 4. Linking of the tyrosinase and 12A probes to adjacent SacII fragments. In the left-hand panel, DNA was digested to completion with BssHII, and then with increasing amounts of SacII to achieve partial digestion. In the right-hand panel, DNA was digested with SacII alone or in combina-tion with BssHII. The map below is the Interpretation of the bands detected. DNA was resolved by OFAGE (250 V, 120 sec pulse, 47 h) and a Southern blot hybridized sequentially with a tyrosinase cDNA (TYR) and the 12A probe. Probe was removed between hybridizations. Frag-ment sizes given in kb were estimated from the migration of chromosome of S. cerevisiae AB972. L indicates the limiting mobility region of the gel. 
H I200kb 
H lOOOkb 
H 580kb 
In order to be able to use tyrosinase probes as Start points for chromosomal 
jumps to progress towards the locus, Information concerning the orientation of the 
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tyrosinase gene and restriction sites within and flanking it is required. Fig. 3D depicts 
Sites close to tyrosinase, taken from the data in Table 1. Since the location of the Xhol 
and Narl sites within the 100 kb cloned around the gene are known, the transcriptional 
orientation can be inferred. 
Conclusions and Perspectives 
The properties of a set of mRNAs whose abundance is reduced in the livers of 
albino lethal mice have been examined in order to come to an understanding of the 
nature of the perinatal lethal phenotype. The mRNAs do not constitute a homogeneous 
collection: they encode Polypeptides of diverse function; they possess different tissue-
specificities, although all are most abundant in liver; the kinetics of their expression in 
newborn liver are not identical, although a subset exhibit a transient induction soon after 
birth. It should be stressed, however, that it cannot be assumed at this stage that each 
mRNA is influenced in the same way by the mutation, and this must lead to caution in 
drawing conclusions. Nuclear run-on assays are presently in progress to determine 
whether the mRNAs are all affected at the transcriptional level, as is the case of 
PEPCK and TAT (Loose et al., 1986; E. Schmid, S.R., unpublished observations), and 
to what extent. Similarly, it is not yet possible to distinguish between primary and 
secondary effects of the mutation on these mRNAs. The recent Observation that the 
abundance of a mRNA encoding a putative transcription factor, the CAAT-box/enhancer 
binding protein (C/EBP, Landschulz et al., 1988), is also reduced in livers of albino 
lethal mice might imply a hierarchy of events (Ruppert et a l , 1989). 
A common property of the mRNAs remains their regulation by hormones, 
glucocorticoids and/or cAMP. Thus, in agreement with Gluecksohn-Waelsch (1987), a 
failure in the induction process appears to be the underlying lesion in these mice. The 
Observation that in the kidney PEPCK can be regulated by glucocorticoids and is 
influenced by the mutation whilst aldolase B and metallothionein I are not regulated and 
not influenced is an interesting coincidence that needs further investigation. The 
response of all of the mRNAs to hormonal Stimuli in vivo is being analysed in order to 
test how general this correlation is. Important for any model for the function of the 
product of the perinatal survival locus is whether all or only a subset of glucocorticoid 
and cAMP regulated genes are deficient in the affected tissues. We do not detect a 
difference in the expression of mRNAs encoding the glucocorticoid receptor or cAMP-
dependent protein kinase subunits between wild-type and mutant mice (Ruppert et al , 
1989). 
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The question as to where the primary lesion in the perinatal lethality lies remains 
open and, hence, the function of the product of the perinatal survival locus remains 
elusive. Two possibilities may be envisaged. The factor encoded by the locus might 
have a direct effect on the transcription of the set of genes. For example, by operating 
at the level of DNA:protein interaction or chromatin structure it might confer to the 
genes the competence to respond to their activators, as advanced by Gluecksohn-
Waelsch (1987). Alternatively, the effect of the mutation might be less direct in that the 
absence of the normal gene product may interfere with some other stage of the pathway 
of transducing a Signal from the extracellular domain to the responsive genes in the 
nucleus. An argument in favour of the latter is the altered properties of selected 
membranes in the affected cells (Trigg and Gluecksohn-Waelsch, 1973). Any model 
must account for the fact that the phenotype is cell-specific, and the mutation has 
pleiotropic effects within the cell and interferes with more than one induction process. 
Ultimately, the understanding of the gene product, and associated deficient 
phenotype, lies in the isolation of the perinatal survival locus. This is being approached 
by the generation of a molecular map of the region of the chromosome surrounding the 
locus and by positioning the various £ locus deletions within it. The map is being used 
to guide the construction of chromosome jumping libraries (Poustka et al., 1987). For 
example, a jump of 230 kb has been made from a Smal site within the tyrosinase gene 
to a Smal site associated with the BssHII/Nael/Narl Cluster (see Fig. 3C and D) pro-
ximal to the gene (A.S., G.K., unpublished observations). This Cluster could then be 
shown to be retained in two out of five deletions of the Bi complementation group. 
These deletions remove c but not the perinatal survival locus (Fig. 3A; Russell et al., 
1982). This new probe, therefore, allows the locus to be excluded from a further region 
of the map. Given that it does not presuppose a mechanism of action of the normal 
gene, this approach to pinpoint the locus is a promising one. 
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